Melanotan I
Afamelanotide · Scenesse · MT-1 · NDP-MSH
A synthetic linear analog of alpha-melanocyte-stimulating hormone ([Nle4-D-Phe7]-alpha-MSH) that acts as a melanocortin (MC1R-preferring) agonist to stimulate eumelanin synthesis. Marketed as afamelanotide (Scenesse), an FDA-approved subcutaneous implant for photoprotection in erythropoietic protoporphyria.
Half-life
Intrinsic peptide half-life short (under ~1 h); the approved implant (Scenesse) is a bioresorbable subcutaneous depot releasing over about 2 days. Half-life is an educational pharmacology figure, drawn from public sources, and is not a schedule or dosing instruction.
Storage & handling
The approved form is a sterile bioresorbable implant kept refrigerated. Research lyophilized powder is kept cold and protected from light; reconstituted solution refrigerated.
References
- FDA label: Scenesse (afamelanotide, 2019)
- EMA: Scenesse
- Peer-reviewed [Nle4-D-Phe7]-alpha-MSH / MC1R pharmacology
Related in Sexual / Hormonal
Educational reference only, compiled from public sources. Not medical advice, diagnosis, treatment, or a dosing recommendation, and not a recommendation to use any compound. Many compounds listed are research materials not approved for human use. Consult a qualified professional.